


# Dolutegravir plus abacavir-lamivudine beats combo therapy

7 November 2013



(HealthDay)—For patients with HIV-1 infection and HIV-1 RNA of 1,000 copies per mL or more, treatment with dolutegravir plus abacavir-lamivudine (DTG-ABC-3TC) is more effective through 48 weeks than combination therapy with efavirenz-tenofovir disoproxil fumarate (DF)-emtricitabine (EFV-TDF-FTC), according to a study published in the Nov. 7 issue of the *New England Journal of Medicine*.

Sharon L. Walmsley, M.D., from the University Health Network in Toronto, and colleagues conducted a randomized, double-blind, phase 3 study involving 833 treatment-naive adult participants with an HIV-1 RNA level of 1,000 copies per mL or more. Participants were randomly allocated to receive DTG-ABC-3TC or [combination therapy](#) with EFV-TDC-FTC.

The researchers found that the proportion of [patients](#) with an HIV-1 RNA level of less than 50 copies per mL was significantly higher in the DTG-ABC-3TC group (88 percent) than in the EFV-TDF-FTC group (81 percent) at week 48, meeting the criteria for superiority. The median time to viral suppression was shorter in the DTG-ABC-3TC group, and there were greater increases in the CD4+ T-cell count than with EFV-TDF-FTC. A lower proportion of patients in the DTG-ABC-3TC group discontinued [therapy](#) because of adverse

events.

"Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine," the authors write.

The study was funded by ViiV Healthcare, the manufacturer and/or marketer of dolutegravir and abacavir-lamivudine.

**More information:** [Full Text \(subscription or payment may be required\)](#)

Copyright © 2013 [HealthDay](#). All rights reserved.

APA citation: Dolutegravir plus abacavir-lamivudine beats combo therapy (2013, November 7) retrieved 21 July 2022 from <https://medicalxpress.com/news/2013-11-dolutegravir-abacavir-lamivudine-combo-therapy.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*